

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

May 17, 2021

Scrip Code: **524816**

Corporate Relationship Department M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

<u>Mumbai 400 001</u>

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

M. Adinarayana

Company Secretary &

MAwarayuna

Vice President (Legal and Corp Affairs



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/4/2021-22

PRESS RELEASE

NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

Hyderabad, India, May 17, 2021

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the signing of a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in India. In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India.

NATCO had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (CDSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp. Affairs)